TY - CHAP
T1 - Irreversible electroporation of pancreatic tumors
AU - Meijerink, Martijn R.
AU - Nilsson, Anders
AU - Narayanan, Govindarajan
AU - Martin, Robert
PY - 2017
Y1 - 2017
N2 - Over 95% of pancreatic cancers are exocrine tumors that bare a dismal prognosis. Although oncological outcome is best for patients presenting with nonmetastatic resectable disease, cure is rarely achieved [1]. Up to 40% of patients present with nonmetastatic disease that is considered unresectable due to vascular encasement (locally advanced pancreatic carcinoma or LAPC) [1, 2]. These patients are nowadays routinely offered systemic chemotherapy with or without radiotherapy. Irreversible electroporation (IRE) represents a promising new method for focal destruction of pancreatic tumors. Evidence to support its effectiveness is gradually surfacing.
AB - Over 95% of pancreatic cancers are exocrine tumors that bare a dismal prognosis. Although oncological outcome is best for patients presenting with nonmetastatic resectable disease, cure is rarely achieved [1]. Up to 40% of patients present with nonmetastatic disease that is considered unresectable due to vascular encasement (locally advanced pancreatic carcinoma or LAPC) [1, 2]. These patients are nowadays routinely offered systemic chemotherapy with or without radiotherapy. Irreversible electroporation (IRE) represents a promising new method for focal destruction of pancreatic tumors. Evidence to support its effectiveness is gradually surfacing.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054941914&origin=inward
U2 - https://doi.org/10.1007/978-3-319-55113-5_11
DO - https://doi.org/10.1007/978-3-319-55113-5_11
M3 - Chapter
SN - 9783319551128
T3 - Irreversible Electroporation in Clinical Practice
SP - 167
EP - 190
BT - Irreversible Electroporation in Clinical Practice
PB - Springer International Publishing
ER -